CancerPPD 2.0 - Browse by Length

Please wait...

Browsing by Length

Browse Results:

Filter by Year
From
Upto

ID	PMID	YEAR	Sequence	Name	Length	Linear/Cyclic	Chirality	Chem-MOD	C-ter MOD	N-ter MOD	Nature	Origin	Cell Line	Cancer Type	Assay	Activity	Testing Time	Tissue Affected	Patents
7624	37104235	2023	QHWSYGLRPGGRGPKDAVRAVKGSALLPCIIVHDPNLNNSDKMKFNTYYLLEYKEYWHQLWSQIIPAHQTVKIQERTGISEVVQNSMIEDLNMYIGADFGMYFYLRSSGFKEQITRGLNRPLSQTTTQLGERVEEMEYYNSNDLDVRYVKYALAREFTLKRVNGEIVKNWVAVDYRMAGIQSYPNAPITNPLTLT	LHRH-BinBC	195	Linear	L	None	Free	Fused a luteinizing hormone-releasing hormone (LHRH) peptide	Mosquitocidal, Anticancer	Synthetic	MCF-7	Breast Cancer	LDH leakage assay	40% LDH efflux at 16 µM	48-h	Breast	None
7623	37104235	2023	QHWSYGLRPGGRGPKDAVRAVKGSALLPCIIVHDPNLNNSDKMKFNTYYLLEYKEYWHQLWSQIIPAHQTVKIQERTGISEVVQNSMIEDLNMYIGADFGMYFYLRSSGFKEQITRGLNRPLSQTTTQLGERVEEMEYYNSNDLDVRYVKYALAREFTLKRVNGEIVKNWVAVDYRMAGIQSYPNAPITNPLTLT	LHRH-BinBC	195	Linear	L	None	Free	Fused a luteinizing hormone-releasing hormone (LHRH) peptide	Mosquitocidal, Anticancer	Synthetic	MCF-7	Breast Cancer	MTT assay	IC₅₀ = 10.96 μM	48-h	Breast	None
6509	33044599	2020	MTTESKVKNATTLLHSGKVKERQEGLSALRNIFSQNSSIERFYNVAGRDGRKPSHEIWAPILDGLQTCIRSEKSAFVTAKKSTDVIEKRLAAAAGTYRWFVEKSMMHFAKKTVLEICHFLYREMKVRETLIPSVALDFIKAYECVASHPPHLARLEEDEIEWEE	Latcripin-7A	164	Linear	L	None	Free	Free	Anticancer	Lentinula edodes	MDA-MB-231	Breast Cancer	CCK-8 assay	IC₅₀ = 122 μg/mL	48-h	Breast	None
6508	33044599	2020	MTTESKVKNATTLLHSGKVKERQEGLSALRNIFSQNSSIERFYNVAGRDGRKPSHEIWAPILDGLQTCIRSEKSAFVTAKKSTDVIEKRLAAAAGTYRWFVEKSMMHFAKKTVLEICHFLYREMKVRETLIPSVALDFIKAYECVASHPPHLARLEEDEIEWEE	Latcripin-7A	164	Linear	L	None	Free	Free	Anticancer	Lentinula edodes	MCF-7	Breast Cancer	CCK-8 assay	IC₅₀ = 91 μg/mL	48-h	Breast	None
6454	32069989	2020	HGDNNSKPKPGGNSGNRGNNGDGASAKVGEITITPDNSKPGRYISSNPEYSLLAKLIDAESIKGTEVYTFHTRKGQYVKVTVPDSNIDKMRVDYVNWKGPKYNNKLVKRFVSQFLLFRKEEKEKNEKEALLKASELVSGMGDKLGEYLGVKYKNVAKEVANDIKNFHGRNIRSYNEAMASLNKVLANPKMKVNKSDKDAIVNAWKQVNAKDMANKIGNLGKAFKVADLAIKVEKIREKSIEGYNTGNWGPLLLEVESWIIGGVVAGVAISLFGAVLSFLPISGLAVTALGVIGIMTISYLSSFIDANRVSNINNIISSVIR	Colicin N	321	Linear	L	None	Free	Free	Antimicrobial	NA	NCI-H23	Lung Cancer	MTT assay	Dose dependent % cell viability resuctuction at 1-15 µM	24-h	Lung	None
6453	32069989	2020	HGDNNSKPKPGGNSGNRGNNGDGASAKVGEITITPDNSKPGRYISSNPEYSLLAKLIDAESIKGTEVYTFHTRKGQYVKVTVPDSNIDKMRVDYVNWKGPKYNNKLVKRFVSQFLLFRKEEKEKNEKEALLKASELVSGMGDKLGEYLGVKYKNVAKEVANDIKNFHGRNIRSYNEAMASLNKVLANPKMKVNKSDKDAIVNAWKQVNAKDMANKIGNLGKAFKVADLAIKVEKIREKSIEGYNTGNWGPLLLEVESWIIGGVVAGVAISLFGAVLSFLPISGLAVTALGVIGIMTISYLSSFIDANRVSNINNIISSVIR	Colicin N	321	Linear	L	None	Free	Free	Antimicrobial	NA	H-292	Lung Cancer	MTT assay	Dose dependent % cell viability resuctuction at 1-15 µM	24-h	Lung	None
6452	32069989	2020	HGDNNSKPKPGGNSGNRGNNGDGASAKVGEITITPDNSKPGRYISSNPEYSLLAKLIDAESIKGTEVYTFHTRKGQYVKVTVPDSNIDKMRVDYVNWKGPKYNNKLVKRFVSQFLLFRKEEKEKNEKEALLKASELVSGMGDKLGEYLGVKYKNVAKEVANDIKNFHGRNIRSYNEAMASLNKVLANPKMKVNKSDKDAIVNAWKQVNAKDMANKIGNLGKAFKVADLAIKVEKIREKSIEGYNTGNWGPLLLEVESWIIGGVVAGVAISLFGAVLSFLPISGLAVTALGVIGIMTISYLSSFIDANRVSNINNIISSVIR	Colicin N	321	Linear	L	None	Free	Free	Antimicrobial	NA	H-460	Lung Cancer	MTT assay	Dose dependent % cell viability resuctuction at 1-15 µM	24-h	Lung	None
5955	30013033	2018	MANCVVGYIGERCQYRDLKWWELRGGGGSGGGGSAPAFSVSPASGLSDGQSVSVSVSGAAAGETYYIAQCAPVGGQDACNPATATSFTTDASGAASFSFVVRKSYTGSTPEGTPVGSVDCATAACNLGAGNSGLDLGHVALTFGGGGGSGGGGSDHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCKLEHHHHHH	Ec-LDP-hBD1	198	Linear	L	None	Free	Free	Antitumor	Synthetic	PG-BE1	Lung Cancer	CCK-8 assay	IC₅₀ = 31.3 μM	24-h	Lung	None
5954	30013033	2018	MANCVVGYIGERCQYRDLKWWELRGGGGSGGGGSAPAFSVSPASGLSDGQSVSVSVSGAAAGETYYIAQCAPVGGQDACNPATATSFTTDASGAASFSFVVRKSYTGSTPEGTPVGSVDCATAACNLGAGNSGLDLGHVALTFGGGGGSGGGGSDHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCKLEHHHHHH	Ec-LDP-hBD1	198	Linear	L	None	Free	Free	Antitumor	Synthetic	H-460	Lung Cancer	CCK-8 assay	IC₅₀ = 5.19 μM	24-h	Lung	None
5953	30013033	2018	MANCVVGYIGERCQYRDLKWWELRGGGGSGGGGSAPAFSVSPASGLSDGQSVSVSVSGAAAGETYYIAQCAPVGGQDACNPATATSFTTDASGAASFSFVVRKSYTGSTPEGTPVGSVDCATAACNLGAGNSGLDLGHVALTFGGGGGSGGGGSDHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCKLEHHHHHH	Ec-LDP-hBD1	198	Linear	L	None	Free	Free	Antitumor	Synthetic	A-549	Lung Cancer	CCK-8 assay	IC₅₀ = 11.9 μM	24-h	Lung	None
5952	30013033	2018	MANCVVGYIGERCQYRDLKWWELRGGGGSGGGGSAPAFSVSPASGLSDGQSVSVSVSGAAAGETYYIAQCAPVGGQDACNPATATSFTTDASGAASFSFVVRKSYTGSTPEGTPVGSVDCATAACNLGAGNSGLDLGHVALTFGGGGGSGGGGSDHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCKLEHHHHHH	Ec-LDP-hBD1	198	Linear	L	None	Free	Free	Antitumor	Synthetic	A-431	Skin Cancer	CCK-8 assay	IC₅₀ = 1.8 μM	24-h	Skin	None
5317	26519876	2016	SLFELGKMILQETGKNPAKSYGAYGCNCGVLGRGGPKDATDRCCYVHKCCYKKLTGCDPKKDRYSYSWKDKTIVCGENNPCLKELCECDKAVAICLRENLGTYNKKYRYHLKPFCKKADPC	BnSP-6	133	Linear	L	None	Free	Free	Antitumor	B. pauloensis	MDA-MB-231	Breast Cancer	MTT assay	45% cell cytotoxicity at 100 μg/mL	24-h	Breast	None
3828	23034893	2012	MDSNKDERAYAQWVIIILHNVGSSPFKIANLGLSWGKLYADGNKDKEVYP SDYNGKTVGPDEKIQINSCGRENASSGTEGSFDIVDPNDGNKTIRHFYWECPWGS KRNTWTPSGSNTKWMVEWSGQNLDSGALGTITVDVLRKGN	AAD (or Aa-Pri1)	145	Linear	L	None	Free	Free	Antitumor	Purified from Agrocybe aegerita	SH-SY5Y	Brain Tumor	MTT/MTS assay	At 2.5 µM concentration,decrease in cell vibility= 70%	48-h	Brain	None
3827	23034893	2012	MDSNKDERAYAQWVIIILHNVGSSPFKIANLGLSWGKLYADGNKDKEVYP SDYNGKTVGPDEKIQINSCGRENASSGTEGSFDIVDPNDGNKTIRHFYW ECPWGSKRNTWTPSGSNTKWMVEWSGQNLDSGALGTITVDVLRKGN	AAD (or Aa-Pri1)	145	Linear	L	None	Free	Free	Antitumor	Purified from Agrocybe aegerita	HeLa	Cervical Cancer	MTT/MTS assay	At 2.5 µM concentration,decrease in cell vibility= 70%	48-h	Cervix	None
3826	23034893	2012	MDSNKDERAYAQWVIIILHNVGSSPFKIANLGLSWGKLYADGNKDKEVY PSDYNGKTVGPDEKIQINSCGRENASSGTEGSFDIVDPNDGNKTIRHFYW ECPWGSKRNTWTPSGSNTKWMVEWSGQNLDSGALGTITVDVLRKGN	AAD (or Aa-Pri1)	145	Linear	L	None	Free	Free	Antitumor	Purified from Agrocybe aegerita	HepG-2	Liver Cancer	MTT/MTS assay	At 2.5 µM concentration,decrease in cell vibility= 35%	48-h	Liver	None
3824	22963485	2012	MNFQQRLQSLWTLARPFCPPLLATASQMQMVVLPCLGFTLLLWSQVSG AQGQEFHFGPCQVKGVVPQKLWEAFWAVKDTMQAQDNITSARLLQQEVLQ NVSDAESCYLVHTLLEFYLKTVFKNYHNRTVEVRTLKSFSTLANNF VLIVSQLQPSQENEMFSIRDSAHRRFLLFRRAFKQL	RGD-mda-7	207	Linear	L	None	Free	Free	Anticancer	Derived from wtmda-7/IL-24 by insertion og a glycine residue between Arg(164) and Asp(165).	Ket-3	Tumor	MTT assay	Apoptotic rate(%)= >50% at concentration of 8 µg/ml	72-h	Not Available	None
3823	22963485	2012	MNFQQRLQSLWTLARPFCPPLLATASQMQMVVLPCLGFTLLLWSQVSG AQGQEFHFGPCQVKGVVPQKLWEAFWAVKDTMQAQDNITSARLLQQEVLQ NVSDAESCYLVHTLLEFYLKTVFKNYHNRTVEVRTLKSFSTLANNF VLIVSQLQPSQENEMFSIRGDSAHRRFLLFRRAFK QLDVEAALTKALGEVDILLTWMQKFYKL	RGD-mda-7	207	Linear	L	None	Free	Free	Anticancer	Derived from wtmda-7/IL-24 by insertion og a glycine residue between Arg(164) and Asp(165).	MCF-7	Breast Cancer	MTT assay	Apoptotic rate(%)= >70% at concentration of 8 µg/ml	72-h	Breast	None
3821	22963485	2012	MNFQQRLQSLWTLARPFCPPLLATASQMQMVVLPCLGFTLLLWSQVSG AQGQEFHFGPCQVKGVVPQKLWEAFWAVKDTMQAQDNITSARLLQQEVLQ NVSDAESCYLVHTLLEFYLKTVFKNYHNRTVEVRTLKSFSTLANNF VLIVSQLQPSQENEMFSIRDSAHRRFLLFRRAF KQL	wtmda-7/IL-24	206	Linear	L	None	Free	Free	Anticancer	NA	Ket-3	Tumor	MTT assay	Apoptotic rate(%)= >30% at concentration of 8 µg/ml	72-h	Not Available	None
3820	22963485	2012	MNFQQRLQSLWTLARPFCPPLLATASQMQMVVLPCLGFTLLLWSQVSG AQGQEFHFGPCQVKGVVPQKLWEAFWAVKDTMQAQDNITSARLLQQEVLQ NVSDAESCYLVHTLLEFYLKTVFKNYHNRTVEVRTLKSFSTLANN FVLIVSQLQPSQENEMFSIRDSAHRRFLLFRRAF KQL	wtmda-7/IL-24	206	Linear	L	None	Free	Free	Anticancer	NA	MCF-7	Breast Cancer	MTT assay	Apoptotic rate(%)= >50% at concentration of 8 µg/ml	72-h	Breast	None
3819	22963485	2012	MNFQQRLQSLWTLARPFCPPLLATASQMQMVVLPCLGFTLLLWSQVSG AQGQEFHFGPCQVKGVVPQKLWEAFWAVKDTMQAQDNITSARLLQQEVLQ NVSDAESCYLVHTLLEFYLKTVFKNYHNRTVEVRTLKSFSTLANN FVLIVSQLQPSQENEMFSIRGDSAHRRFLLFRRAF KQLDVEAALTKALGEVDILLTWMQKFYKL	RGD-mda-7	207	Linear	L	None	Free	Free	Anticancer	Derived from wtmda-7/IL-24 by insertion og a glycine residue between Arg(164) and Asp(165).	Ket-3	Tumor	MTT/MTS assay	Cell viability(% of control)= 0.5 at concentration 8 µg/ml	48-h	Not Available	None
3818	22963485	2012	MNFQQRLQSLWTLARPFCPPLLATASQMQMVVLPCLGFTLLLWSQVSG AQGQEFHFGPCQVKGVVPQKLWEAFWAVKDTMQAQDNITSARLLQQEVLQ NVSDAESCYLVHTLLEFYLKTVFKNYHNRTVEVRTLKSFSTLANN FVLIVSQLQPSQENEMFSIRGDSAHRRFLLFRRAF KQLDVEAALTKALGEVDILLTWMQKFYKL	RGD-mda-7	207	Linear	L	None	Free	Free	Anticancer	Derived from wtmda-7/IL-24 by insertion og a glycine residue between Arg(164) and Asp(165).	MCF-7	Breast Cancer	MTT/MTS assay	Cell viability(% of control)=0.5 at concentration 4 µg/ml	48-h	Breast	None
3817	22963485	2012	MNFQQRLQSLWTLARPFCPPLLATASQMQMVVLPCLGFTLLLWSQVSG AQGQEFHFGPCQVKGVVPQKLWEAFWAVKDTMQAQDNITSARLLQQEVLQ NVSDAESCYLVHTLLEFYLKTVFKNYHNRTVEVRTLKSFSTLANN FVLIVSQLQPSQENEMFSIRDSAHRRFLLFRRA FKQL	wtmda-7/IL-24	206	Linear	L	None	Free	Free	Anticancer	NA	Ket-3	Tumor	MTT/MTS assay	Cell viability(% of control)= 0.5 at concentration 8 µg/ml	48-h	Not Available	None
3816	22963485	2012	MNFQQRLQSLWTLARPFCPPLLATASQMQMVVLPCLGFTLLLWSQVSG AQGQEFHFGPCQVKGVVPQKLWEAFWAVKDTMQAQDNITSARLLQQEVLQ NVSDAESCYLVHTLLEFYLKTVFKNYHNRTVEVRTLKSFSTLAN NFVLIVSQLQPSQENEMFSIRDSAHRRFLLFRRA FKQL	wtmda-7/IL-24	206	Linear	L	None	Free	Free	Anticancer	NA	MCF-7	Breast Cancer	MTT/MTS assay	Cell viability(% of control)=0.5 at concentration 7 µg/ml	48-h	Breast	None
4690	26125720	2007	QPVLHLVALNTPLSGGMRGIRGADFQCFQQARAVGLSGTFRAFLSSRLQDLYSIVRRADRGSVPIVNLKDEVLSPSWDSLFSGSQGQLQPGARIFSFDGRDVLRHPAWPQKSVWHGSDPSGRRLMESYCETWRTETTGATGQASSLLSGRLLEQKAASCHNSYIVLCIENSF	Endostatin	172	Linear	L	None	Free	Free	Antiangiogenic	P. pastoris	MFC	Stomach Cancer	IP injections	Tumor inhibition rate = 72.89%	14 days	Stomach	None